Gilead leads rivals in race to cure hepatitis C

Home › Gilead leads rivals in race to cure hepatitis C

Gilead Sciences' Sovaldi can cure as many as 90 percent of hepatitis C patients in 12 to 24 weeks.

14.06	DTS report finds US in-vehicle video and gaming growing rapidly
14.06	Atlantic Tropical Weather Outlook
14.06	Eastern North Pacific Tropical Weather Outlook
14.06	Improved drought conditions? Whats the pollination season look like?
14.06	EXCEDE for Swine rapidly reaches therapeutic plasma concentration levels
14.06	Lessons learned from wean-to-harvest biosecurity program
14.06	Atlantic Tropical Weather Outlook
14.06	Eastern North Pacific Tropical Weather Outlook
More »

je.st